Advancing Precision Oncology Through Integrated Discovery Science
The oncology and immuno-oncology drug discovery landscape is evolving at unprecedented speed. Advances in molecular biology, genomics, and immune science have enabled the emergence of targeted therapies, immunotherapies, and novel modalities such as protein degraders, antibody-based therapeutics, and cell- and gene-based approaches. These innovations are reshaping how cancer is treated—yet significant scientific and translational challenges remain.
Cancer is highly heterogeneous, driven by complex molecular networks, adaptive resistance mechanisms, and dynamic tumor–immune interactions. Successfully translating promising concepts into viable drug candidates requires deep biological insight, robust experimental systems, and tightly integrated discovery strategies.
We support oncology and immuno-oncology programs with end-to-end, preclinical discovery solutions, designed to help our partners navigate biological complexity, reduce development risk, and accelerate confident decision-making.
Comprehensive Support Across Oncology Therapeutic Modalities
Our oncology and immuno-oncology capabilities are designed to evaluate and advance a wide range of therapeutic strategies, including:
✅ Small molecules and peptides
✅ RNA- and DNA-based therapeutics
From oncogenic signaling pathways to immune activation and tumor microenvironment modulation, our scientific teams deliver mechanism-informed solutions tailored to each program’s unique objectives.
Broad Target Coverage and Translationally Relevant Assays
We offer extensive expertise across oncology-relevant target classes, including (but not limited to):
✅ Protein–protein interaction targets
✅ Innate and adaptive immune signaling pathways
Our assay strategies integrate biochemical, biophysical, cellular, and phenotypic approaches, enabling confident evaluation of target engagement, functional activity, and pathway modulation. Translationally relevant cellular systems help bridge early discovery findings to downstream biological outcomes.
Integrated Oncology Discovery Strategy
Traditional, siloed discovery approaches often fail to capture the full biological complexity of cancer. Our model emphasizes integration across disciplines, combining biology, pharmacology, and translational science to guide programs from early hypothesis through candidate selection.
Key elements of our integrated approach include:
✅ Rational screening cascade design
✅ Mechanism-driven lead optimization
✅ Early assessment of selectivity,
safety, and developability
This holistic framework allows us to identify risks early, prioritize the most promising assets, and improve overall program efficiency.
Deep Scientific Expertise and Collaborative Partnership
What truly differentiates our oncology and immuno-oncology offering is the depth of scientific experience behind it.
Our teams include seasoned scientists and project leaders with extensive backgrounds in oncology research and drug discovery across pharmaceutical, biotechnology, and academic environments. This experience translates into:
✅ Strong biological and translational insight
✅ Data-driven experimental design
✅ Clear, actionable interpretation of results
We work collaboratively with our partners, acting as a true extension of their discovery teams—aligning scientific strategy, timelines, and decision points from the outset.
Translational Oncology and Preclinical Study Design
To support informed progression decisions, we design tailored preclinical studies that integrate:
✅ Pharmacology and target engagement
✅ Biomarker identification and validation
✅ Resistance and combination strategy evaluation
Our translational mindset ensures that preclinical data are decision-enabling, supporting downstream development planning while remaining firmly rooted in discovery-stage objectives.
Our Oncology Discovery Philosophy
At the core of our approach is a commitment to rigorous science, thoughtful integration, and practical impact. We recognize that cancer is not a single disease and that effective therapies often emerge at the intersection of oncology, immunology, and broader disease biology.
By combining cross-disciplinary expertise with flexible discovery platforms, we help our partners move from innovative ideas to high-quality drug candidates with confidence.
Partner With Us
Whether you are exploring a novel oncology target, advancing an immuno-oncology concept, or optimizing a complex therapeutic modality, we offer the expertise, infrastructure, and collaborative mindset to support your program’s success.
Together, we help turn scientific insight into meaningful oncology drug discovery progress.
